Publications by Jochen Schwenk
Refereegranskade
Artiklar
[1]
X. Yu et al., "Advances in plasma proteomics : Moving from technology to precision medicine," PROTEOMICS - Clinical Applications, vol. 16, no. 6, 2022.
[2]
C. E. Thomas et al., "Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer," Translational Oncology, vol. 17, pp. 101339, 2022.
[3]
A. Wesolowska-Andersen et al., "Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals : An IMI DIRECT study," CELL REPORTS MEDICINE, vol. 3, no. 1, 2022.
[4]
Z. Yang et al., "Genetic Landscape of the ACE2 Coronavirus Receptor," Circulation, vol. 145, no. 18, pp. 1398-1411, 2022.
[5]
R. Gurke et al., "Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis," Biomedicines, vol. 10, no. 10, 2022.
[6]
X. Yu et al., "Advances in plasma proteomics : Call for papers for an upcoming special issue," PROTEOMICS - Clinical Applications, vol. 15, no. 6, 2021.
[7]
M. Stockfelt et al., "Circulating proteins associated with allergy development in infants-an exploratory analysis," Clinical Proteomics, vol. 18, no. 1, 2021.
[8]
M. Zeybel et al., "Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients," Molecular Systems Biology, vol. 17, no. 10, 2021.
[9]
C. Wu et al., "Elevated circulating follistatin associates with an increased risk of type 2 diabetes," Nature Communications, vol. 12, no. 1, 2021.
[10]
M. J. Iglesias et al., "Identification of Endothelial Proteins in Plasma Associated With Cardiovascular Risk Factors," Arteriosclerosis, Thrombosis and Vascular Biology, vol. 41, no. 12, pp. 2990-3004, 2021.
[11]
A. Gummesson et al., "Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes," EBioMedicine, vol. 63, 2021.
[12]
N. Roxhed et al., "Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2," Nature Communications, vol. 12, no. 1, 2021.
[13]
W. Bauer et al., "Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection," Viruses, vol. 13, no. 12, pp. 2456, 2021.
[14]
R. Bizzotto, J. M. Schwenk and A. Mari, "Processes Underlying Glycemic Deterioration in Type 2 Diabetes : An IMI DIRECT Study," Diabetes Care, vol. 44, no. 2, pp. 511-518, 2021.
[15]
A. Tura, J. M. Schwenk and A. Mari, "Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT : An IMI DIRECT Study," Diabetes, vol. 70, no. 9, pp. 2092-2106, 2021.
[16]
E. W. Deutsch et al., "p Advances and Utility of the Human Plasma Proteome," Journal of Proteome Research, vol. 20, no. 12, pp. 5241-5263, 2021.
[17]
N. Bar et al., "A reference map of potential determinants for the human serum metabolome," Nature, vol. 588, no. 7836, pp. 135-140, 2020.
[18]
R. Eriksen, J. M. Schwenk and G. Frost, "Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk : An IMI DIRECT study," EBioMedicine, vol. 58, 2020.
[19]
Å. Sivertsson et al., "Enhanced Validation of Antibodies Enables the Discovery of Missing Proteins," Journal of Proteome Research, vol. 19, no. 12, pp. 4766-4781, 2020.
[20]
T. Dodig-Crnkovic et al., "Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling," EBioMedicine, vol. 57, 2020.
[21]
K. Suhre, M. I. McCarthy and J. M. Schwenk, "Genetics meets proteomics : perspectives for large population-based studies," Nature reviews genetics, 2020.
[22]
K. Drobin et al., "Molecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer," Cancers, vol. 12, no. 3, 2020.
[23]
M. Dezfouli et al., "Newborn Screening for Presymptomatic Diagnosis of Complement and Phagocyte Deficiencies," Frontiers in Immunology, vol. 11, 2020.
[24]
M. Obura et al., "Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes : An IMI-DIRECT study," PLOS ONE, vol. 15, no. 11, 2020.
[25]
N. Atabaki-Pasdar et al., "Predicting and elucidating the etiology of fatty liver disease : A machine learning modeling and validation study in the IMI DIRECT cohorts," PLoS Medicine, vol. 17, no. 6, 2020.
[26]
M.-G. Hong et al., "Profiles of histidine-rich glycoprotein associate with age and risk of all-cause mortality," Life Science Alliance, vol. 3, no. 10, pp. e202000817, 2020.
[27]
R. W. Koivula et al., "The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes : an IMI DIRECT study," Diabetologia, vol. 63, no. 4, pp. 744-756, 2020.
[28]
V. Gudmundsdottir et al., "Whole blood co-expression modules associate with metabolic traits and type 2 diabetes : an IMI-DIRECT study," Genome Medicine, vol. 12, no. 1, 2020.
[29]
W. Zhong et al., "Whole-genome sequence association analysis of blood proteins in a longitudinal wellness cohort," Genome Medicine, vol. 12, no. 1, 2020.
[30]
A. Andersson et al., "Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease," Clinica Chimica Acta, vol. 494, pp. 79-93, 2019.
[31]
R. W. Koivula, J. M. Schwenk and P. W. Franks, "Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes : descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium," Diabetologia, vol. 62, no. 9, pp. 1601-1615, 2019.
[32]
H. R. Wilman et al., "Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration," Journal of Hepatology, vol. 71, no. 3, pp. 594-602, 2019.
[33]
M. Pernemalm et al., "In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta," eLIFE, vol. 8, 2019.
[34]
V. Ignjatovic et al., "Mass Spectrometry-Based Plasma Proteomics : Considerations from Sample Collection to Achieving Translational Data," Journal of Proteome Research, vol. 18, no. 12, pp. 4085-4097, 2019.
[35]
E. Lorenzen et al., "Multiplexed analysis of the secretin-like GPCR-RAMP interactome," Science Advances, vol. 5, no. 9, 2019.
[36]
G. S. Omenn et al., "Progress on Identifying and Characterizing the Human Proteome : 2019 Metrics from the HUPO Human Proteome Project," Journal of Proteome Research, vol. 18, no. 12, pp. 4098-4107, 2019.
[37]
F. Edfors et al., "Screening a Resource of Recombinant Protein Fragments for Targeted Proteomics," Journal of Proteome Research, vol. 18, no. 7, pp. 2706-2718, 2019.
[38]
R. S. Häussler et al., "Systematic Development of Sandwich Immunoassays for the Plasma Secretome," Proteomics, 2019.
[39]
C. Fredolini et al., "Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles," Scientific Reports, vol. 9, 2019.
[40]
K. Drobin et al., "Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci," Inflammatory Bowel Diseases, vol. 25, no. 2, pp. 306-316, 2019.
[41]
[42]
S. Byström et al., "Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density," Breast Cancer Research, vol. 20, 2018.
[43]
[44]
D. Djureinovic et al., "Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer," Lung Cancer, 2018.
[45]
L. P. Matic et al., "Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage," JACC: Basic to Translational Science, vol. 3, no. 4, pp. 464-480, 2018.
[46]
G. S. Omenn et al., "Progress on Identifying and Characterizing the Human Proteome : 2018 Metrics from the HUPO Human Proteome Project," Journal of Proteome Research, vol. 17, no. 12, pp. 4031-4041, 2018.
[47]
B. Glimelius et al., "U-CAN : a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden," Acta Oncologica, vol. 57, no. 2, pp. 187-194, 2018.
[48]
B. Omazic et al., "A Preliminary Report : Radical Surgery and Stem Cell Transplantation for the Treatment of Patients with Pancreatic Cancer," Journal of immunotherapy (1997), vol. 40, no. 4, pp. 132-139, 2017.
[49]
M. Uhlén et al., "A pathology atlas of the human cancer transcriptome," Science, vol. 357, no. 6352, pp. 660-+, 2017.
[50]
[51]
S. Byström et al., "Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence," Translational Oncology, vol. 10, no. 3, pp. 385-395, 2017.
[52]
L. Lourido et al., "Discovery of circulating proteins associated to knee radiographic osteoarthritis," Scientific Reports, vol. 7, 2017.
[53]
E. Pin et al., "Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer," Journal of Proteome Research, vol. 16, no. 1, pp. 204-216, 2017.
[54]
H. Idborg et al., "PROTEIN PROFILING IN PLASMA REVEALS MOLECULAR SUBGROUPS IN SYSTEMIC LUPUS ERYTHEMATOSUS," Annals of the Rheumatic Diseases, vol. 76, pp. A52-A52, 2017.
[55]
J. M. Schwenk et al., "The Human Plasma Proteome Draft of 2017 : Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays," Journal of Proteome Research, vol. 16, no. 12, pp. 4299-4310, 2017.
[56]
X. Zhou et al., "Thiol–ene–epoxy thermoset for low-temperature bonding to biofunctionalized microarray surfaces," Lab on a Chip, vol. 17, no. 21, pp. 3672-3681, 2017.
[57]
A. Zandian et al., "Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis," Translational Psychiatry, vol. 7, 2017.
[58]
A. Zandian et al., "Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy," Journal of Proteome Research, vol. 16, no. 3, pp. 1300-1314, 2017.
[59]
U. Qundos et al., "Affinity proteomics discovers decreased levels of AMFR in plasma from Osteoporosis patients," PROTEOMICS - Clinical Applications, vol. 10, no. 6, pp. 681-690, 2016.
[60]
B. Ayoglu et al., "Anoctamin 2 identified as an autoimmune target in multiple sclerosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 8, pp. 2188-2193, 2016.
[61]
B. Ayoglu, J. M. Schwenk and P. Nilsson, "Antigen arrays for profiling autoantibody repertoires," Bioanalysis, vol. 8, no. 10, pp. 1105-1126, 2016.
[62]
A. Häggmark-Månberg et al., "Autoantibody targets in vaccine-associated narcolepsy," Autoimmunity, vol. 49, no. 6, pp. 421-433, 2016.
[63]
J. Remnestål et al., "CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease," PROTEOMICS - Clinical Applications, vol. 10, no. 12, pp. 1242-1253, 2016.
[64]
C. Hamsten et al., "Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients," Respiratory Research, vol. 17, 2016.
[65]
M. Mikus et al., "Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury," Liver international (Print), vol. 37, no. 1, pp. 132-140, 2016.
[66]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," New Biotechnology, vol. 33, no. 5, pp. 582-592, 2016.
[67]
C. Fredolini et al., "Immunocapture strategies in translational proteomics," Expert Review of Proteomics, vol. 13, no. 1, pp. 83-98, 2016.
[68]
M.-G. Hong et al., "Multidimensional Normalization to Minimize Plate Effects of Suspension Bead Array Data," Journal of Proteome Research, vol. 15, no. 10, pp. 3473-3480, 2016.
[69]
B. Ayoglu et al., "Multiplexed protein profiling by sequential affinity capture," Proteomics, vol. 16, no. 8, pp. 1251-1256, 2016.
[70]
A. Häggmark, J. M. Schwenk and P. Nilsson, "Neuroproteomic profiling of human body fluids," PROTEOMICS - Clinical Applications, vol. 10, no. 4, pp. 485-502, 2016.
[71]
M. Bruzelius et al., "PDGFB, a new candidate plasma biomarker for venous thromboembolism : Results from the VEREMA affinity proteomics study," Blood, vol. 128, no. 23, pp. e59-e66, 2016.
[72]
M. J. Iglesias et al., "An affinity proteomics study for plasma biomarker candidates of cardiovascular disease in venous thromboembolism," Journal of Thrombosis and Haemostasis, vol. 13, pp. 956-956, 2015.
[73]
G. O'Hurley et al., "Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer," PLOS ONE, vol. 10, no. 8, 2015.
[74]
P. Arner et al., "Circulating Carnosine Dipeptidase 1 associates with weight loss and poor prognosis in gastrointestinal cancer," PLOS ONE, vol. 10, no. 4, 2015.
[75]
C. Hamsten et al., "Heat differentiated complement factor profiling," Journal of Proteomics, vol. 126, pp. 155-162, 2015.
[76]
K. Papp et al., "Multiplex measurement of autoantibody levels and complement activation in rheumatoid arthritis," Molecular Immunology, vol. 67, no. 1, pp. 170-170, 2015.
[77]
A. Häggmark et al., "Proteomic Profiling Reveals Autoimmune Targets in Sarcoidosis," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 5, pp. 574-583, 2015.
[78]
M. Uhlén et al., "Tissue-based map of the human proteome," Science, vol. 347, no. 6220, pp. 1260419, 2015.
[79]
M. Bruzelius et al., "Verema - an affinity proteomics study to identify and translate plasma biomarkers for venous thromboembolism," Journal of Thrombosis and Haemostasis, vol. 13, pp. 954-954, 2015.
[80]
S. Byström et al., "Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue within Multiple Sclerosis," Journal of Proteome Research, vol. 13, no. 11, pp. 4607-4619, 2014.
[81]
J. Bachmann et al., "Affinity Proteomics Reveals Elevated Muscle Proteins in Plasma of Children with Cerebral Malaria," PLoS Pathogens, vol. 10, no. 4, pp. e1004038, 2014.
[82]
B. Ayoglu et al., "Affinity proteomics within rare diseases : a BIO-NMD study for blood biomarkers of muscular dystrophies," EMBO Molecular Medicine, vol. 6, no. 7, pp. 918-936, 2014.
[83]
F. Henjes et al., "Analysis of Autoantibody Profiles in Osteoarthritis Using Comprehensive Protein Array Concepts," Journal of Proteome Research, vol. 13, no. 11, pp. 5218-5229, 2014.
[84]
U. Qundos et al., "Analysis of plasma from prostate cancer patients links decreased carnosine dipeptidase 1 levels to lymph node metastasis," Translational Proteomics, vol. 2, no. 1, pp. 14-24, 2014.
[85]
L. Fagerberg et al., "Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics," Molecular & Cellular Proteomics, vol. 13, no. 2, pp. 397-406, 2014.
[86]
A. N. Kremer et al., "Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation," Haematologica, vol. 99, no. 2, pp. 365-369, 2014.
[87]
M. Dezfouli et al., "Magnetic bead assisted labeling of antibodies at nanogram scale," Proteomics, vol. 14, no. 1, pp. 14-18, 2014.
[88]
M. Dezfouli et al., "Parallel barcoding of antibodies for DNA-assisted proteomics," Proteomics, vol. 14, no. 21-22, pp. 2432-2436, 2014.
[89]
A. Häggmark et al., "Plasma profiling revelas three proteins associated to amyotrophic lateral sclerosis," Annals of Clinical and Translational Neurology, vol. 1, no. 8, pp. 544-553, 2014.
[90]
A. Danielsson et al., "The Human Pancreas Proteome Defined by Transcriptomics and Antibody-Based Profiling," PLOS ONE, vol. 9, no. 12, pp. e115421, 2014.
[91]
A. Häggmark et al., "Antibody-based profiling of cerebrospinal fluid within multiple sclerosis," Proteomics, vol. 13, no. 15, pp. 2256-2267, 2013.
[92]
B. Ayoglu et al., "Autoantibody profiling in multiple sclerosis using arrays of human protein fragments," Molecular & Cellular Proteomics, vol. 12, no. 9, pp. 2657-2672, 2013.
[93]
L. Fagerberg et al., "Contribution of antibody-based protein profiling to the human chromosome-centric proteome project (C-HPP)," Journal of Proteome Research, vol. 12, no. 6, pp. 2439-2448, 2013.
[94]
K. Drobin, P. Nilsson and J. M. Schwenk, "Highly multiplexed antibody suspension bead arrays for plasma protein profiling," Methods in Molecular Biology, vol. 1023, pp. 137-145, 2013.
[95]
S. Darmanis et al., "Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors," PLOS ONE, vol. 8, no. 11, pp. e81712, 2013.
[96]
U. Qundos et al., "Profiling post-centrifugation delay of serum and plasma with antibody bead arrays," Journal of Proteomics, vol. 95, no. SI, pp. 46-54, 2013.
[97]
M. Neiman et al., "Selectivity analysis of single binder assays used in plasma protein profiling," Proteomics, vol. 13, no. 23-24, pp. 3406-3410, 2013.
[98]
A. Asplund et al., "Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research," Proteomics, vol. 12, no. 13, pp. 2067-2077, 2012.
[99]
K. Colwill et al., "A roadmap to generate renewable protein binders to the human proteome," Nature Methods, vol. 8, no. 7, pp. 551-8, 2011.
[100]
J. M. Schwenk and P. Nilsson, "Antibody suspension bead arrays," Methods in molecular biology (Clifton, N.J.), vol. 723, pp. 29-36, 2011.
[101]
A. Häggmark et al., "Classification of protein profiles from antibody microarrays using heat and detergent treatment.," New Biotechnology, vol. 29, no. 5, pp. 564-570, 2011.
[102]
B. Hjelm et al., "Generation of monospecific antibodies based on affinity capture of polyclonal antibodies," Protein Science, vol. 20, no. 11, pp. 1824-1835, 2011.
[103]
M. Neiman et al., "Plasma Profiling Reveals Human Fibulin-1 as Candidate Marker for Renal Impairment," Journal of Proteome Research, vol. 10, no. 11, pp. 4925-4934, 2011.
[104]
B. Ayoglu et al., "Systematic antibody and antigen-based proteomic profiling with microarrays," EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. 11, no. 2, pp. 219-234, 2011.
[105]
F. Pontén et al., "The Human Protein Atlas as a proteomic resource for biomarker discovery," Journal of Internal Medicine, vol. 270, no. 5, pp. 428-446, 2011.
[106]
R. Sjöberg et al., "Validation of affinity reagents using antigen microarrays," New Biotechnology, vol. 29, no. 5, pp. 555-563, 2011.
[107]
B. S. Kato et al., "Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model," Proteome Science, vol. 9, no. 1, pp. 73, 2011.
[108]
J. Gantelius et al., "A lateral flow protein microarray for rapid determination of contagious bovine pleuropneumonia status in bovine serum," Journal of Microbiological Methods, vol. 82, no. 1, pp. 11-18, 2010.
[109]
C. Eriksson et al., "Affibody molecule-mediated depletion of HSA and IgG using different buffer compositions : a 15 min protocol for parallel processing of 1-48 samples," Biotechnology and applied biochemistry, vol. 56, pp. 49-57, 2010.
[110]
J. M. Schwenk et al., "Comparative protein profiling of serum and plasma using an antibody suspension bead array approach," Proteomics, vol. 10, no. 3, pp. 532-540, 2010.
[111]
J. M. Schwenk et al., "Toward Next Generation Plasma Profiling via Heat-induced Epitope Retrieval and Array-based Assays," Molecular & Cellular Proteomics, vol. 9, no. 11, pp. 2497-2507, 2010.
[112]
K. Larsson et al., "Characterization of PrEST-based antibodies towards human Cytokeratin-17," JIM - Journal of Immunological Methods, vol. 342, pp. 20-32, 2009.
[113]
N. LeBlanc et al., "Development of a magnetic bead microarray for simultaneous and simple detection of four pestiviruses," Journal of Virological Methods, vol. 155, pp. 1-9, 2009.
[114]
J. Rockberg, J. M. Schwenk and M. Uhlén, "Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies," Molecular Oncology, vol. 3, no. 3, pp. 238-247, 2009.
[115]
J. Gantelius et al., "Magnetic bead-based detection of autoimmune responses using protein microarrays.," New biotechnology, vol. 26, pp. 269-276, 2009.
[116]
M. Neiman et al., "Multiplex Screening of Surface Proteins from Mycoplasma mycoides subsp mycoides Small Colony for an Antigen Cocktail Enzyme-Linked Immunosorbent Assay," Clinical and Vaccine Immunology, vol. 16, no. 11, pp. 1665-1674, 2009.
[117]
C. Hamsten et al., "Recombinant surface proteomics as a tool to analyze humoral immune responses in bovines infected by Mycoplasma mycoides subsp. mycoides SC," Molecular & Cellular Proteomics, vol. 8, no. 11, pp. 2544-2554, 2009.
[118]
R. Rimini et al., "Validation of serum protein profiles by a dual antibody array approach," , vol. 73, no. 2, pp. 252-266, 2009.
[119]
J. M. Schwenk et al., "Antibody suspension bead arrays within serum proteomics," Journal of Proteome Research, vol. 7, no. 8, pp. 3168-3179, 2008.
[120]
J. M. Schwenk et al., "Determination of binding specificities in highly multiplexed bead-based assays for antibody proteomics," Molecular & Cellular Proteomics, vol. 6, no. 1, pp. 125-132, 2007.
Kapitel i böcker
[121]
M. J. Iglesias, J. M. Schwenk and J. Odeberg, "Affinity Proteomics Assays for Cardiovascular and Atherosclerotic Disease Biomarkers," in Protein Microarrays for Disease Analysis : Methods and Protocols, : Springer Nature, 2021, pp. 163-179.
[122]
A. Bendes et al., "Bead-Based Assays for Validating Proteomic Profiles in Body Fluids," in Protein Microarrays for Disease Analysis : Methods and Protocols, : Springer Nature, 2021, pp. 65-78.
[123]
R. Sjöberg et al., "High-density antigen microarrays for the assessment of antibody selectivity and off-target binding," in Epitope Mapping Protocols, : Humana Press Inc., 2018, pp. 231-238.
[124]
B. Ayoglu, P. Nilsson and J. M. Schwenk, "Multiplexed antigen bead arrays for the assessment of antibody selectivity and epitope mapping," in Epitope Mapping Protocols, : Humana Press Inc., 2018, pp. 239-248.
[125]
E. Birgersson, J. . M. Schwenk and B. Ayoglu, "Bead-based and multiplexed immunoassays for protein profiling via sequential affinity capture," in Serum/Plasma Proteomics, : Humana Press, 2017, pp. 45-54.
[126]
C. Hellström et al., "High-density serum/plasma reverse phase protein arrays," in Serum/Plasma Proteomics, : Humana Press, 2017, pp. 229-238.
[127]
A. Häggmark-Månberg, P. Nilsson and J. Schwenk, "Neuroproteomic profiling of cerebrospinal fluid (CSF) by multiplexed affinity arrays," in Neuroproteomics : Methods and Protocols, : Humana Press, 2017, pp. 247-254.
[128]
J. M. Schwenk and P. Nilsson, "Assessment of antibody specificity using suspension bead arrays.," in Methods in Molecular Biology, : Springer, 2011, pp. 183-189.
Icke refereegranskade
Artiklar
[129]
C. E. Thomas et al., "Individual effects of gastric bypass surgery on longitudinal blood protein profiles : an IMI DIRECT study," Diabetologia, vol. 62, pp. S271-S271, 2019.
[130]
M. Persson et al., "Searching for Novel Autoantibodies with Clinical Relevance in Psychiatric Disorders," Schizophrenia Bulletin, vol. 44, pp. S120-S121, 2018.
[131]
D. Djureinovic et al., "Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer," Journal of Thoracic Oncology, vol. 12, no. 11, pp. S2002-S2002, 2017.
[132]
L. Lourido et al., "IDENTIFICATION OF A SERUM PROTEIN BIOMARKER PANEL FOR THE DIAGNOSIS OF KNEE OSTEOARTHRITIS," Osteoarthritis and Cartilage, vol. 24, pp. S23-S23, 2016.
[133]
L. Lourido et al., "DISCOVERY OF POTENTIAL SERUM BIOMARKERS IN OSTEOARTHRITIS USING PROTEIN ARRAYS," Annals of the Rheumatic Diseases, vol. 74, pp. 373-374, 2015.
[134]
L. Lourido et al., "Discovery of Novel Serum Biomarkers for Osteoarthritis Using Affinity Proteomics," Arthritis & Rheumatology, vol. 67, 2015.
[135]
B. Ayoglu et al., "Proteomic profiling of the autoimmunity repertoire in multiple sclerosis," New Biotechnology, vol. 29, pp. S20-S20, 2012.
Övriga
[136]
J. Hauser et al., "A Microfluidic Device for Patient-Centric Multiplexed Assays with Readout in Centralized Laboratories," (Manuscript).
[137]
[138]
S. Byström et al., "Affinity proteomic profiling of plasma for proteins associated to mammographic breast density," (Manuscript).
[139]
S. Byström et al., "Affinity proteomics exploration of melanoma identifies proteins in serum with associations to T-stage and recurrence," (Manuscript).
[140]
[141]
M. Dezfouli et al., "Droplet-based Immuno-Sequencing to Deconvolute Affinity Recognition Events," (Manuscript).
[142]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," (Manuscript).
[143]
U. Qundos et al., "Plasma levels of carnosine dipeptidase 1 decrease in prostate cancer patients with lymph node metastasis," (Manuscript).
[144]
B. Ayoglu et al., "The calcium-activated chloride channel anoctamine 2 as an autoimmune component of multiple sclerosis," (Manuscript).
[145]
M. Neiman et al., "Validating the selectivity of antibodies used in multiplexed serum profiling via parallel immunocapture analysis," (Manuscript).
Senaste synkning med DiVA:
2023-03-19 17:36:31